Recursion Pharmaceuticals is trading at $3.67, down 4.18%, and available coverage does not establish a specific reason for the November 3 decline.
- The company reported Q3 results on November 2: revenue of $18.55 million beat estimates, and its $0.22 per-share loss was narrower than expected.
- Biotech was rising, which does not explain the stock’s decline. Earnings results are relevant timing, but the evidence does not show they caused the move.